Free · no account · quoted from the filing

What changed in CNC's 10-Q

Source: 10-Q filed 2026-04-28 · compared against 10-Q 2025-10-29. Every passage below is quoted verbatim from the filing itself.

Divestitures

This filing
the Company recorded impairment charges associated with the pending divestiture totaling $513 million, or $389 million after-tax

Liquidity

This filing
The maximum outstanding purchase amount permitted under the agreement is $4,250 million

Medical Cost Trend

This filing
We continue to observe and respond to elevated medical cost trend impacting the industry in recent years

Marketplace

This filing
we are operating in an evolving regulatory and market landscape that has contributed to overall market contraction and shifts in member metal tier distribution across carriers

Regulatory

This filing
The OBBBA, passed in July 2025, includes requirements that may reduce the number of members eligible for state Medicaid Expansion programs

Legal

This filing
Rosenbaum v. London, et. al, (filed January 30, 2026) in the District of Delaware
What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.